Overview

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-03-31

Target enrollment:

Participant gender:

Summary

This is an open-label, single center, one cohort, non-randomized, phase II study. The aim of the study is to evaluate the efficacy and safety of the combination of nivolumab and ipilimumab with nogapendekin alfa inbakicept in patients with stage IV or recurrent non-small cell lung cancer (NSCLC). It is hypothesized that the study treatment will be safe and well tolerated and will improve progression-free survival when compared to a historical study which treated advanced NSCLC patients with nivolumab plus ipilimumab. Patients will be treated in cycles lasting 6 weeks with two to three different chemotherapy drugs to up to 24 months.

Phase:

PHASE2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

ImmunityBio, Inc.
The Foundation for Barnes-Jewish Hospital

Treatments:

ALT-803
Ipilimumab
Nivolumab